YAP/TEAD4-reagulated placental alkaline phosphatases ALPP and ALPPL2 are immunosuppressive ectonucleotidases modulated by MAPK inhibitors
Bauche, D.; Martin, J. L.; Huang, B.; Ehrenberger, T.; Hasan, A. R.; Dow, M.; Khoo, W. H.; Pacaud, R.; Metwally, E.; Porth, K.; Kim, G.; McKenna, S.; Li, C.; Ho, N.; Nguyen, K.; Hahn, S.; Rath, B.; sathiyamoorthy, K.; Ho, s. w. s.; Yang, P.; Olow, A.; Sadekova, S.
Show abstract
Placental alkaline phosphatases ALPP and ALPPL2 (ALPP/L2) are promising clinical targets for therapies such as antibody-drug conjugates (ADCs). However, their regulation and biological functions remain unclear. Here, we identify the YAP/TEAD4 signaling axis as the primary regulator of ALPP/L2 expression in tumor cells. Importantly, we demonstrate that inhibitors targeting KRAS, MEK, and ERK upregulate ALPP/L2 expression in vitro and in vivo, thereby enhancing the efficacy of antibody-drug conjugates (ADCs) when used in combination. Moreover, our work reveals a novel immunomodulatory function of ALPP/L2 as cell surface ectonucleotidases that hydrolyze extracellular ATP, ADP, and AMP to adenosine, promoting regulatory T cell infiltration into the tumor microenvironment. Together, these findings reveal a biological function of ALPP/L2 and identify druggable regulators to enhance ALPP/L2-targeted therapies. SIGNIFICANCEThis study uncovers the YAP/TEAD pathway as a positive regulator of the clinically relevant tumor-associated antigens ALPP and ALPPL2. Kras, MEK, or ERK inhibitors enhance ALPP/L2 expression in tumor cells, thereby increasing the efficacy of ALPP/L2-targeted antibody-drug conjugates. These findings offer a promising combination strategy to overcome resistance to ALPP/L2-based therapies caused by low target expression.
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- A focal adhesion kinase-YAP signaling axis drives drug tolerant persister cells and residual disease in lung cancer 98%
- Coupling cellular drug-target engagement to downstream pharmacology with CeTEAM 98%
- An integrative oncogene-dependency map identifies unique vulnerabilities of oncogenic EGFR, KRAS, and RIT1 in lung cancer 97%
Similar papers in this journal
- EZH2 synergizes with BRD4-NUT to drive NUT carcinoma growth through silencing of key tumor suppressor genes 98%
- Pharmacologically targeting KRASG12D in PDAC models:tumor cell intrinsic and extrinsic impact 97%
- PAX3-FOXO1 drives targetable cell state-dependent metabolic vulnerabilities in rhabdomyosarcoma 97%
Similar papers in this journal
Similar papers in this journal
- Glutamine mimicry suppresses tumor progression through asparagine metabolism in pancreatic ductal adenocarcinoma 97%
- Combined KRASG12C and SOS1 inhibition enhances and extends the anti-tumor response in KRASG12C-driven cancers by addressing intrinsic and acquired resistance 96%
- Cancer-associated fibroblast compositions change with breast cancer progression linking S100A4 and PDPN ratios with clinical outcome 96%
Similar papers in this journal
- Interrogation of cancer gene dependencies reveals novel paralog interactions of autosome and sexchromosome encoded genes 96%
- Genetic dependencies associated with transcription factor activities in human cancer cell lines 96%
- Targeting KRAS-mutant stomach/colorectal tumours by disrupting the ERK2-p53 complex 96%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.